Published in N Engl J Med on May 20, 1971
Human cytomegalovirus infection of the monocyte/macrophage lineage in bone marrow. J Virol (1994) 2.31
Candidate cytomegalovirus strain for human vaccination. Infect Immun (1975) 1.99
Production and characterization of monoclonal antibodies specific for a glycosylated polypeptide of human cytomegalovirus. J Clin Microbiol (1983) 1.91
Role of chronic hepatitis in development of thalassaemic liver disease. Arch Dis Child (1976) 1.80
Cytomegalovirus: Clinical virological correlations in renal transplant recipients. Ann Surg (1974) 1.34
Hemorrhage from cecal ulcers of cytomegalovirus infection: report of a case. Ann Surg (1973) 1.30
Treatment of congenital cytomegalovirus infection: implications for future therapeutic strategies. J Antimicrob Chemother (2009) 1.30
Immunity to human cytomegalovirus measured and compared by complement fixation, indirect fluorescent-antibody, indirect hemagglutination, and enzyme-linked immunosorbent assays. J Clin Microbiol (1984) 1.19
Cytomegalovirus infection in a volunteer blood donor population. Infect Immun (1975) 1.18
Recent clinical isolates of cytomegalovirus suppress human cytomegalovirus-specific human leukocyte antigen-restricted cytotoxic T-lymphocyte activity. J Virol (1986) 1.13
Infectious mononucleosis and mononucleosis syndromes. West J Med (1977) 1.02
Cell-mediated and humoral immune responses or renal transplant recipients with cytomegalovirus infections. Clin Exp Immunol (1974) 0.98
Cytomegalovirus infection in children undergoing open-heart surgery. Yale J Biol Med (1976) 0.97
Increased IgM and IgM immune complex-like material in the circulation of renal transplant recipients with primary cytomegalovirus infections. Clin Exp Immunol (1982) 0.97
Cytomegalovirus hijacks CX3CR1(hi) patrolling monocytes as immune-privileged vehicles for dissemination in mice. Cell Host Microbe (2014) 0.94
Anticomplement immunofluorescence test that uses isolated fibroblast nuclei for detection of antibodies to human cytomegalovirus. J Clin Microbiol (1980) 0.91
Bench-to-bedside review: rare and common viral infections in the intensive care unit--linking pathophysiology to clinical presentation. Crit Care (2008) 0.90
The blood donor: detection and magnitude of cytomegalovirus carrier states and the prevalence of cytomegalovirus antibody. Yale J Biol Med (1976) 0.90
Cytomegalovirus infection and immunity in renal allograft recipients: assessment of the competence of humoral immunity. Infect Immun (1976) 0.89
Cytomegalovirus infections in the blood recipient. Yale J Biol Med (1976) 0.83
Cell-mediated and humoral immune responses to herpes simplex virus and cytomegalovirus in renal transplant patients. J Clin Microbiol (1979) 0.83
Host responses to Epstein-Barr virus and cytomegalovirus infection in leprosy. Infect Immun (1973) 0.83
Non-A, non-B hepatitis. Yale J Biol Med (1976) 0.82
Cytomegalovirus (CMV) antibody screening in blood donors: modification of new latex agglutination test compared with two standard methods. J Clin Pathol (1987) 0.78
Blood transusion: use and abuse of blood components. West J Med (1978) 0.76
Cytomegalovirus-induced haemolytic anaemia after cardiac surgery. Thorax (1976) 0.76
Transfusion-associated cytomegalovirus mononucleosis. Ann Surg (1977) 0.75
The mystique of the herpesviruses. Calif Med (1973) 0.75
Study of the Frequency of Herpesvirus Infections Among Patients Suspected Aseptic Meningitis in the West of Iran. Jundishapur J Microbiol (2015) 0.75
Cytomegalovirus: a cause of persistent latent infection. J Clin Pathol Suppl (R Coll Pathol) (1972) 0.75
Cytomegalovirus-mononucleosis in a newborn infant. Arch Dis Child (1975) 0.75
Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med (1980) 9.34
An antigen detected in the blood during the incubation period of serum hepatitis. Proc Natl Acad Sci U S A (1968) 7.33
Hepatocellular carcinoma and the hepatitis B virus: evidence for a causal association. Prog Med Virol (1978) 5.02
On the role of sexual behavior in the spread of hepatitis B infection. Ann Intern Med (1975) 4.11
Serum hepatitis antigen (SH): rapid detection by high voltage immunoelectroosmophoresis. Science (1970) 4.00
Genomic structure of the human prototype strain H of hepatitis C virus: comparison with American and Japanese isolates. Proc Natl Acad Sci U S A (1991) 3.34
The e antigen and vertical transmission of hepatitis B surface antigen. Am J Epidemiol (1977) 3.07
The role of circulating hepatitis B antigen/antibody immune complexes in the pathogenesis of vascular and hepatic manifestations in polyarteritis nodosa. J Clin Pathol (1974) 2.85
Long-incubation post-transfusion hepatitis without serological evidence of exposure to hepatitis-B virus. Lancet (1974) 2.77
A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report. Hepatology (1982) 2.74
Hepatitis B virus vaccine: identification of HBsAg/a and HBsAg/d but not HBsAg/y subtype antigenic determinants on a synthetic immunogenic peptide. Proc Natl Acad Sci U S A (1982) 2.52
Serum alanine aminotransferase of donors in relation to the risk of non-A,non-B hepatitis in recipients: the transfusion-transmitted viruses study. N Engl J Med (1981) 2.29
Sensitivity of serological assays to identify blood donors with hepatitis C viraemia. Lancet (1992) 2.25
Efficacy of hepatitis B immune globulin for prevention of perinatal transmission of the hepatitis B virus carrier state: final report of a randomized double-blind, placebo-controlled trial. Hepatology (1983) 2.22
Hepatitis A virus infection: new insights from seroepidemiologic studies. J Infect Dis (1978) 2.21
Immunologic distinction between infectious and serum hepatitis. N Engl J Med (1970) 2.16
HBeAg and anti-HBe detection by radioimmunoassay: correlation with vertical transmission of hepatitis B virus in Taiwan. J Med Virol (1979) 2.06
Hepatitis B virus antibody in blood donors and the occurrence of non-A, non-B hepatitis in transfusion recipients. An analysis of the Transfusion-Transmitted Viruses Study. Ann Intern Med (1984) 2.01
Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy. N Engl J Med (1984) 1.93
Hepatitis B infection. A point-prevalence study in 15 US hemodialysis centers. JAMA (1974) 1.92
Specificity of the direct solid-phase radioimmunoassay for detection of hepatitis-B antigen. Lancet (1973) 1.89
The prevalence of antibody to hepatitis A antigen in various parts of the world: a pilot study. Am J Epidemiol (1977) 1.86
Role of serum hepatitis virus in chronic liver disease. Gastroenterology (1971) 1.84
Isolation of a simian immunodeficiency virus related to human immunodeficiency virus type 2 from a west African pet sooty mangabey. J Virol (1991) 1.82
Distribution of antibody to hepatitis a antigen in urban adult populations. N Engl J Med (1976) 1.81
Relation of Australia and SH antigens. Lancet (1968) 1.75
Incidence of hepatitis B virus infections in preschool children in Taiwan. J Infect Dis (1982) 1.74
Viral syndromes and renal homograft rejection. Ann Surg (1972) 1.74
Hepatitis B antigen (HBSAg) and/or antibodies (anti-HBS and anti-HBC) in fulminant hepatitis: pathogenic and prognostic significance. Gut (1976) 1.74
The association of viral and mycoplasma infections with recurrence of wheezing in the asthmatic child. Ann Allergy (1970) 1.70
Antibodies to a synthetic peptide from the preS 120-145 region of the hepatitis B virus envelope are virus neutralizing. Vaccine (1986) 1.68
Hepatitis B "immune" globulin: effectiveness in prevention of dialysis-associated hepatitis. N Engl J Med (1975) 1.66
Recent advances in the study of the epidemiology of hepatitis B. Am J Pathol (1975) 1.64
Antibody-dependent enhancement of human immunodeficiency virus type 1 (HIV-1) infection in vitro by serum from HIV-1-infected and passively immunized chimpanzees. Proc Natl Acad Sci U S A (1989) 1.64
Passive immunotherapy in the treatment of advanced human immunodeficiency virus infection. J Infect Dis (1993) 1.63
Regulated processing of hepatitis C virus core protein is linked to subcellular localization. J Virol (1997) 1.63
Familial clustering of hepatitis B infection. N Engl J Med (1973) 1.56
Low level rubella immunity detected by ELISA and specific lymphocyte transformation. Arch Virol (1980) 1.55
Prevalence of antibody to the Norwalk virus in various countries. Infect Immun (1979) 1.54
S.H. antigen and chronic liver disease. Lancet (1970) 1.51
Intrafamilial spread of asymptomatic hepatitis B. Am J Med Sci (1977) 1.48
Prevention of HIV-1 IIIB infection in chimpanzees by CD4 immunoadhesin. Nature (1991) 1.47
Hepatitis B antigen and antibody in blood donors: an epidemiologic study. J Infect Dis (1973) 1.46
Hepatitis B vaccine in medical staff of hemodialysis units: efficacy and subtype cross-protection. N Engl J Med (1982) 1.46
Coxsackievirus and adenovirus infection. Association with acute febrile and juvenile rheumatoid arthritis. JAMA (1976) 1.45
The use of tri(n-butyl)phosphate detergent mixtures to inactivate hepatitis viruses and human immunodeficiency virus in plasma and plasma's subsequent fractionation. Transfusion (1990) 1.45
Gamma-glutamyltransferase as a potential surrogate marker for detection of the non-A, non-B carrier state. Vox Sang (1988) 1.44
The epidemiology of hepatitis B infections in Africa: results of a pilot survey in the Republic of Senegal. Am J Epidemiol (1973) 1.43
Prevalence of serum-hepatitis-related antigen (SH) in different geographic regions. Am J Trop Med Hyg (1970) 1.42
The epidemiology of serum hepatitis (SH) infections: a controlled study in two closed institutions. Am J Epidemiol (1971) 1.40
Sounding board. Use of hepatitis B immuneglobulin:reassessment needed. N Engl J Med (1978) 1.40
Virulent HIV strains, chimpanzees, and trial vaccines. Science (1999) 1.40
Virus-like particles in human plasma and serum: role of platelet lysosomes. J Natl Cancer Inst (1966) 1.39
Prevalence, clinical significance, and strain specificity of neutralizing antibody to the human immunodeficiency virus. J Infect Dis (1987) 1.38
Production of albumin and other serum proteins by clonal cultures of normal human liver. Proc Natl Acad Sci U S A (1971) 1.38
Ocular complications in renal transplant recipients. Am J Med (1973) 1.38
The development of virus-free labile blood derivatives--a review. Eur J Epidemiol (1987) 1.33
Molecular cloning and characterization of onchocystatin, a cysteine proteinase inhibitor of Onchocerca volvulus. J Biol Chem (1992) 1.33
Sounding board: Effective primary care by the subspecialty center. N Engl J Med (1975) 1.32
Role of immune complexes involving SH antigen in pathogenesis of chronic active hepatitis and polyarteritis nodosa. Lancet (1971) 1.30
Clinical signs of the pseudoexfoliation syndrome. Ophthalmology (1986) 1.29
Serum hepatitis specific antigen (SH) in commercial and volunteer sources of blood. Transfusion (1971) 1.29
Baseline epidemiological studies for a hepatitis B vaccine trial in Kangwane. S Afr Med J (1983) 1.29
Multicenter seroepidemiologic study of the impact of cytomegalovirus infection on renal transplantation. Transplantation (1985) 1.29
Development and distribution of hemagglutinating antibody against the hepatitis B antigen in institutionalized populations. J Infect Dis (1972) 1.28
Hepatitis B antigen in wild-caught mosquitoes in Africa. Lancet (1972) 1.27
Identification of additional antigenic sites on Dane particles and the tubular forms of hepatitis B surface antigen. J Gen Virol (1976) 1.25
Preclinical diagnosis of pseudoexfoliation syndrome. Arch Ophthalmol (1987) 1.25
A case/control study of the association between primary liver cancer and hepatitis B infection in Senegal. Int J Cancer (1975) 1.24
Use of conserved sequences from hepatitis C virus for the detection of viral RNA in infected sera by polymerase chain reaction. Hepatology (1991) 1.23
Solvent/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma. Blood (1992) 1.22
Three different patterns of hepatitis C virus infection in chimpanzees. Hepatology (1992) 1.21
Ototoxicity induced by furosemide. N Engl J Med (1970) 1.19
Hypericin as an inactivator of infectious viruses in blood components. Transfusion (1995) 1.19
Identification of an immunodominant epitope within the capsid protein of hepatitis C virus. Proc Natl Acad Sci U S A (1991) 1.18
Role of arthropods in transmission of hepatitis-B virus in the tropics. Lancet (1973) 1.17
Passive immunization with a human immunodeficiency virus type 1-neutralizing monoclonal antibody in Hu-PBL-SCID mice: isolation of a neutralization escape variant. J Infect Dis (1998) 1.15
Pharmacokinetics, safety, and antiviral effects of hypericin, a derivative of St. John's wort plant, in patients with chronic hepatitis C virus infection. Antimicrob Agents Chemother (2001) 1.14
Detection of virus-associated antigen in serum and liver of patients with non-A non-B hepatitis. Lancet (1979) 1.14
The serum hepatitis related antigen (SH) in illicit drug users. Am J Epidemiol (1970) 1.13
The nitroblue-tetrazolium test. Usefulness in detecting bacterial infections in uraemic and immunosuppressed renal transplant patients. Lancet (1972) 1.11
Chronic liver disease in asymptomatic narcotic addicts. Ann Intern Med (1972) 1.10
Adrenal glucocorticoids after twenty years. A review of their clinically relevant consequences. J Chronic Dis (1970) 1.10
Hypercalcemia after renal transplantation. Long-term follow-up data. N Engl J Med (1973) 1.09
Immunity in chimpanzees chronically infected with hepatitis C virus: role of minor quasispecies in reinfection. J Virol (1998) 1.09
Detection of e antigen and antibody: correlations with hapatitis B surface and hepatitis B core antigens, liver disease, and outcome in hepatitis B infections. Gastroenterology (1976) 1.09